Foresite Capital Management Iv, LLC Lyell Immunopharma, Inc. Transaction History
Foresite Capital Management Iv, LLC
- $90.8 Million
- Q2 2025
Shares
6 transactions
Others Institutions Holding LYEL
# of Institutions
60Shares Held
109MCall Options Held
2.9KPut Options Held
6K-
Mwg Management Ltd. Washington, DC20.2MShares$213 Million18.54% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$160 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$160 Million9.84% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$143 Million0.0% of portfolio
-
Wu Xi App Tec Co., Ltd. Shanghai, F47.39MShares$78.1 Million53.56% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $2.62B
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...